Condition: Prostate Cancer · Sponsor: Weill Medical College of Cornell University
This is a phase I/II study investigating the combination of 225Ac-J591 (a drug that can deliver radiation to prostate cancer cells) with pembrolizumab (immunotherapy, a drug that increases the immune system's ability to destroy cancer cells). This study will assess whether 225Ac-J591 + pembrolizumab + androgen receptor inhibitor (ARI) is more effective against prostate cancer than pembrolizumab + ARI alone.
This description comes directly from the study's public registry record.
GUONC Research Team · 212-746-1480 · guonc@med.cornell.edu
GUCLINIC Research Team · guclinic@med.cornell.edu
Always discuss trial participation with your own doctor first.
| Dana-Farber Cancer Institute | Boston, Massachusetts, United States | Not Yet Recruiting |
| New York Presbyterian/Brooklyn Methodist Hospital | Brooklyn, New York, United States | Recruiting |
| New York Presbyterian/Weill Cornell Medical Center | New York, New York, United States | Recruiting |
| Columbia University Irving Cancer Center | New York, New York, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04946370